Format: 2017-02-23
Format: 2017-02-23
December 27, 2016 | 115 Pages | SKU: IRTNTR11278

Overview of the global cancer monoclonal antibodies (mAbs) market

Technavio’s market research analyst predicts the global cancer monoclonal antibodies (mAbs) market to grow at a CAGR of around 11% by 2021. At present, the market is witnessing the emergence of targeted and combination therapies for the treatment of cancers and inflammatory diseases. These therapies exploit the surface properties of the infected cells and cause fewer adverse side effects than the conventional non-targeted therapies. As targeting multiple pathways minimizes the threat of developing treatment-resistant disorders, combination therapies are highly preferable in treating cancers. Also, several vendors in the market are collaborating and entering strategic alliances to develop and market the novel drugs. For instance, Seattle Genetics collaborated with Bristol-Myers Squibb to launch a combination of OPDIVO and ADCETRIS to treat hematologic malignancies.

In terms of geography, the cancer mAbs market in the Americas is growing at a steady rate due to the higher acceptance of existing cancer mAbs and the introduction of new ones. Also, the region is likely to witness accelerated approvals for specific formulations and pipeline molecules, encouraging more vendors to conduct research activities in the market. Recently, the US FDA granted accelerated approval to daratumumab injection (DARZALEX) for the treatment of multiple myelomas.

Competitive landscape and key vendors

The global cancer mAbs market is marked by the presence of established vendors such as F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, and Takeda

December 27, 2016 | 86 Pages | SKU: IRTNTR11277

Overview of the global multiple myeloma drugs market

Technavio’s market research analyst predicts the global multiple myeloma drugs market to grow at a CAGR of over 9% between 2017 and 2021.  The market is currently witnessing a paradigm shift towards the implementation of proteasome inhibitors as a key therapeutic strategy in the treatment of multiple myeloma. Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Proteasome inhibitor treatment is preferred after there is a treatment failure with the conventional approach. With the approval of several new proteasome inhibitors, such as Johnson & Johnson's DARZALEX and Takeda Pharmaceuticals' NINLARO, the market is expected to witness steady growth during the forecast period.

The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining huge traction in this market, owing to several limitations of existing technologies. The nanotechnology approach allows much earlier diagnosis or treatment regimes and facilitates the delivery of drugs specifically to cancer cells by directing cellular events at the nanometer scale. One of the key clinical benefits of nanocarrier-based approach over conventional drugs is the precise delivery of several chemotherapeutic agents per recognition event. Also, the particulate nanocarriers and polymer conjugates augment the drug portfolio available to oncologists.

Competitive landscape and key vendors

The global multiple myeloma drugs market is characterized by leading companies such as Celgene, Johnson & Johnson, Takeda Pharmaceuticals, Amgen, and Novartis. The advances in research activities and launch of novel

November 18, 2016 | 101 Pages | SKU: IRTNTR10849

Overview of the lung cancer therapeutics market

According to the market research analysts at Technavio, the lung cancer therapeutics market is anticipated to witness fast-paced growth at a CAGR of more than 9% during the forecast period. With the growing demand for targeted therapies, the market for lung cancer therapeutics is likely to have a positive impact over the coming years. Targeted therapy is a novel treatment that involves targeting cancer-specific proteins, genes, cells or the tissue that leads to cancer growth and survival. Targeted therapies act by blocking the growth and spread of cancer cells besides limiting the damage to healthy cells. Moreover, targeted therapies have better efficacy over conventional therapies such as surgical resection, platinum-based chemotherapy, and radiation therapy. This has impelled the vendors to increasingly focus on developing targeting therapies in combination with traditional ones. Moreover, targeted therapies may have lesser side effects as compared with chemotherapy and radiation, which will lead to their increased adoption by physicians in the future.

In terms of geographical regions, the Americas led the global lung cancer therapeutics market and is likely to be the highest revenue contributor in the coming years. The presence of a large patient pool with lung cancer is one of the primary drivers of this market in the Americas, especially the US. Also, the increasing acceptance of targeted therapy for the treatment of lung cancer will bolster this market’s growth in the region. Some of the existing targeted therapies that are approved by the US FDA include bevacizumab (Avastin), erlotinib (Tarceva), gefitinib (Iressa), and ramucirumab (Cyramza). With the increasing adoption of targeted therapies

September 20, 2016 | 110 Pages | SKU: IRTNTR10286

Overview of the leukemia therapeutics market

According to the market research analysts at Technavio, the leukemia therapeutics market will witness fast-paced growth and will post a staggering CAGR of more than 8% over the forecast period. The application for expanded indication approvals is one of the primary factors driving the growth of this market. The concept of repositioning came into practice in the early 1990s and is based on the possibility that different diseases could be sharing common molecular pathways. This has led several companies to conduct clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is a low-risk, high-reward strategy, it could increase the scope of treatment and help in increased market penetration.

One of the recent trends propelling the growth prospects for this market is the rise in the development of combination therapies to treat leukemia. Combination therapies for the treatment of leukemia are mostly available in the form of combination chemotherapy drugs. Some of the approved combinations include chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of chronic lymphocytic leukemia (CLL); a combination of cytarabine, daunorubicin, and etoposide for the treatment of acute myeloid leukemia (AML); and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of acute lymphocytic leukemia (ALL). These therapies are expected to increase the effectiveness of the treatment, which in turn, will increase the patient compliance toward the use of these drugs.

Competitive landscape and key vendors


September 13, 2016 | 87 Pages | SKU: IRTNTR9914

Overview of the global intracranial pressure (ICP) monitoring market

Market research analysts at Technavio have predicted that the global intracranial pressure (ICP) monitoring market will grow at a CAGR of more than 7% by 2020. The increasing incidence of traumatic brain injury (TBI) cases worldwide is expected to boost the demand for ICP monitors. Factors such as robust guidelines from the healthcare and medical organizations and the development of non-invasive ICP and wireless ICP monitoring systems will also contribute to the growth of this market over the next four years. Also, the use of ICP monitoring across various applications will result in this market’s considerable growth over the next four years. Besides trauma injuries, these monitors have other usages such as for stroke, meningitis, subarachnoid hemorrhage (SAH), hepatic failure, and intracerebral hematoma. These devices are also used during carotid artery surgery and after neurosurgery. In addition, the increasing prevalence of neurological disorders have also surged the adoption of ICP monitoring.

The Americas will be the largest revenue-contributing region in the ICP monitoring market and is projected to occupy more than 56% of the total market revenue during the forecast period. Much of the region’s growth is because of the growing prevalence of TBIs, and the awareness about neurological diseases such as epilepsy and meningitis, which requires individuals to undergo continuous monitoring. The launch of new and technologically advanced products such as invasive and wireless ICP monitoring will spur the growth prospects for the market in the coming years.

Competitive landscape and key vendors

The market

September 06, 2016 | 88 Pages | SKU: IRTNTR10205

Overview of the global breast cancer monoclonal antibodies (mAbs) market

Market research analysts at Technavio have predicted that the global breast cancer monoclonal antibodies (mAbs) market will grow at a CAGR of around 8% between 2016 and 2020.  The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs), including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.

The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist